The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma

Experts explore the clinical significance and practical implications of recent findings regarding a CAR T-cell therapy in real-world settings.

EP. 1: The Expanding Utility of CAR T-Cell Therapy in LBCL

January 30th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.

EP. 2: Sequencing With CAR T-Cell Therapy for LBCL

January 30th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.

EP. 3: CAR T-Cell Therapy as a Second-Line Treatment for LBCL

February 5th 2024

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

EP. 4: Understanding Malignancy Risks With the Use of CAR T-cell Therapies

February 5th 2024

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

EP. 5: Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

February 13th 2024

Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.

EP. 6: Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

February 13th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.

EP. 7: The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

February 20th 2024

Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.

EP. 8: Bridging Therapy With CAR T-Cell Therapy in LBCL

February 20th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

EP. 9: The Future of CAR T-Cell Therapy in LBCL

February 27th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, look at both the regulatory and clinical components that will shape future research and utilization of CAR T-cell therapy in oncology and beyond.

EP. 10: Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

February 27th 2024

Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.